A highly protective and durable pre-erythrocytic CSP-based P. vivax vaccine would have a dual beneficial effect of preventing not only the initial infection but also secondary relapses from hyponozoites thus inhibiting the establishment of latent infection. Here, DNAJC5 is linked to disease arising from reactivation of latent virus.